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Huntington disease (HD) is an autosomal-dominant disorder that results fromR36 CAG repeats in the HD gene (HTT). Approximately
10% of patients inherit a chromosome that underwent CAG expansion from an unaffected parent with <36 CAG repeats. This study is
a comprehensive analysis of genetic diversity in HTT and reveals that HD patients of European origin (n ¼ 65) have a signiﬁcant enrich-
ment (95%) of a speciﬁc set of 22 tagging single nucleotide polymorphisms (SNPs) that constitute a single haplogroup. The disease asso-
ciation ofmany SNPs is much stronger than any previously reported polymorphism andwas conﬁrmed in a replication cohort (n¼ 203).
Importantly, the same haplogroup is also signiﬁcantly enriched (83%) in individuals with 27–35 CAG repeats (intermediate alleles,
n ¼ 66), who are unaffected by the disease, but have increased CAG tract sizes relative to the general population (n ¼ 116). These
data support a stepwise model for CAG expansion into the affected range (R36 CAG) and identiﬁes speciﬁc haplogroup variants in
the general population associated with this instability. The speciﬁc variants at risk for CAG expansion are not present in the general pop-
ulation in China, Japan, and Nigeria where the prevalence of HD is much lower. The current data argue that cis-elements have a major
predisposing inﬂuence on CAG instability in HTT. The strong association between speciﬁc SNP alleles and CAG expansion also provides
an opportunity of personalized therapeutics in HD where the clinical development of only a small number of allele-speciﬁc targets may
be sufﬁcient to treat up to 88% of the HD patient population.Introduction
Huntington disease (HD [MIM 143100]) is a dominantly
inherited progressive neurodegenerative disorder that
results from a mutation that expands the polymorphic
trinucleotide (CAG) tract in HTT. The average control
CAG tract size in the general population is 17–20 repeats.1
However, in HD patients, one of the two copies of the gene
has a CAG tract that has expanded to 36 repeats or more.2
The size of the CAG tract can be unstable and has a bias
toward increasing size, especially when transmitted by the
male germline.3 Initially, the new mutation rate for HD
was believed to be very low, and the disease was limited
to families with a history of HD. Recent estimates have
found that CAG expansion into the disease range is more
common than initially anticipated and the new mutation
rate for HD could be 10% or greater.4,5
Many factorsarebelieved tocontribute toCAGinstability,
including the size of theCAG tract, CAG tract interruptions,
sex andageof the transmittingparent, environmental inﬂu-
ences,6,7 and other genetic cis-elements and trans-factors.8,9
Although a larger CAG tract size and transmission through
the male germline have been clearly demonstrated to
increase CAG instability, trans-factors such as DNA repair
machinery are also believed to play an important contrib-
uting role.10 For instance, the CAG instability of HD trans-
genic mice was rescued when crossed with mice lacking
either the mismatch repair enzymeMSH2 (MIM 609309)11The Ameor the base excision repair enzyme OGG1 (MIM 601982).12
Although cis-elements are known tomodifyCAG instability
inother genes,13 previousdatahave argued against a role for
cis-elements in CAG instability in HTT.14,15
Numerous studies have investigated the origins of the
disease by constructing haplotypes of the HTT region in
speciﬁc ethnic populations.15–30 These studies have been
limited to small sets of allelic markers because, aside from
the CAG tract, only a few polymorphisms in HTT have
been previously characterized.31 Many of these studies
found positive correlations between speciﬁc markers and
disease chromosomes27 and concluded that the HD muta-
tion originates from a common descent, although not
necessarily from a single founder.26–28
To our knowledge, this is the ﬁrst comprehensive
analysis of genetic diversity in HTT on HD (>36 CAG),
intermediate allele (27–35 CAG), and control (<27 CAG)
chromosomes. Despite the genetic diversity around HTT
in the general population, we identify a subset of tagging
single nucleotide polymorphisms (SNPs) that are highly
associated with disease chromosomes (R36 CAG) of Euro-
pean descent. We report many SNPs that are highly sensi-
tive markers of disease chromosomes and have stronger
linkage associations with CAG expansion than any previ-
ously characterized polymorphism in the gene region.
The disease-associated SNPs constitute a cluster of similar
haplotypes (haplogroup A) found on 95% of disease chro-
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Furthermore, we ﬁnd the same haplogroup A is signiﬁ-
cantly enriched on unaffected chromosomes with an
elevated CAG size (27–35 CAG; intermediate alleles) rela-
tive to the general population (15–26 CAG). The presence
of CAG-expanded chromosomes on a single haplogroup
supports the hypothesis that predisposing cis-elements
are a major determinant of CAG instability.
The strong association between speciﬁc SNPs and CAG-
expanded chromosomes now provides an attractive thera-
peutic opportunity for the treatmentofHD.The association
of speciﬁc SNPs combinedwith high rates of heterozygosity
in HD patients provides suitable targets for allele-speciﬁc
knockdown of the mutant gene product.
Material and Methods
Sample Populations
A total of 190 SNPswere identiﬁed andveriﬁed in theHTT regionon
chromosome 4p16.3 through a combination of data from direct
sequencing and phase I/II HapMap Data Coordination Centre
(Figure S1 available online). Direct sequencing was performed on
Canadians of European origin, from the clinical database at the
UniversityofBritishColumbia (UBC)DNAandTissueBank forHun-
tington Disease Research (procedures followed and patient consent
were in accordance with UBC ethics H05-70532-A003). The
HapMap cohort includes 30 trios (mother, father, offspring) from
U.S. residents with northern and western European ancestry (origi-
nally collected by the Centre d’Etude du Polymorphisme Humain),
30 trios from theYorubapeople of Ibadan,Nigeria, and45unrelated
individuals from both Beijing, China and Tokyo, Japan.
DNA from 65 HD patients was included in this study (38 male/
27 female). 30 samples were selected because of trio information
availability and 35 were selected randomly from the UBC database.
A second cohort of 203HDpatientswas used as a replication cohort
to conﬁrm the SNP associations. The control (unaffected spouse)
group consisted of 58 randomly selected subjects (19 male/
29 female). The intermediate allele population have 27–35 CAGs
inHTTandconsistedof66subjects (30male/36 female).Thecohorts
were comprised of mostly Canadians of European descent, with
a small proportion having indigenous Canadian ethnicity (<5%).
Selection and Genotyping of SNPs in HapMap Cohorts
Selection of SNPs was achieved through use of direct sequencing
results, online SNP databases such as the SNP Consortium and
dbSNP, as well as data from Phase I and II of the International
HapMap Project. A total of 190 SNPs were identiﬁed within the
HTT region (Figure S1) and subsequently genotyped in the
HapMap population.32,33
Phylogenetic and Linkage Analysis
Phylogenetic analysis of genotypes was performed with the
Mega3 software.34 Each individual from the HapMap cohort was
compared based on sequence similarity at the 190 SNP positions
to construct a neighbor-joining tree rooted on the chimpanzee
sequence. Linkage disequilibrium (LD) analysis was performed
with Haploview software.35 Linkage plots are displayed with the
standardLDcolor scheme (D’/LOD)where color represents linkage,
in decreasing order: red (LODR 2 and D’¼ 1), pink (LODR 2 and
D’< 1), blue (LOD< 2 andD’¼ 1), andwhite (LOD< 2 andD’< 1).352 The American Journal of Human Genetics 84, 351–366, March 1Determination of tSNP Genotypes and Phasing in HD
Patients and Controls
A panel of 22 nonredundant tSNPs were selected as a means to esti-
mate haplotypes in the HD patients, 27–35 CAG individuals, and
unaffected spouse controls from the general population. Tag SNPs
were selected with the Tagger program.36 Genotyping and phasing
of HD, 27–35 CAG, and controls was performedwith the SNPstream
genotyping assay.37 The methods in brief are described. (1) Primers
for PCR and SNP-IT were designed based on SNP loci and its
appropriate sequencewithweb-basedAutoprimersoftware. (2)Oligo-
nucleotide microarrays were produced in a 384-well plate set-up on
a glass-bottomed plate. (3) Genomic sequences carrying the SNPs of
interest were ampliﬁed in a 12-plex PCR reaction. (4) PCR clean-up
was performed. (5) Post-PCR cycle extension for the SNP-IT reaction.
(6) Assay results were interpreted by two-color ﬂuorescence on
SNPstream UHT Array Imager. (7) Data analysis, quality control,
and graphical interpretation of results were performed on SNPstream
software.Phasingwasperformedby incorporatinggenotype informa-
tion of family trios into PHASE 2.0 software. Direct sequencing of the
CAG tract was performed with primers HTTg010_F (ATTACAGTCT
CACCACGCCC) andHTTg010_R (GACAAGGGAAGACCCAAGTG).
Haplogroups
Individual haplotypes were combined into haplogroups with
speciﬁc tSNPs to deﬁne the groupings. Haplogroup A was deﬁned
with tSNPs that had allele distributions thatwere signiﬁcantly asso-
ciatedwithdisease chromosomes (chi-squarediseaseversus control)
andhadhigh sensitivity (>0.95).HaplogroupsB andCweredeﬁned
manually to classify the remaining haplotypes. The remaining
unclassiﬁed haplotypes were singleton or rare haplotypes and
were put into an ‘‘other’’ haplogroup but are not necessarily related
to each other. Analysis of the haplogroup variants was performed
only on chromosomes that were deﬁned as haplogroup A. Variants
A1–A5 were deﬁned and distinguished from each other with the
remaining tSNPs not used in the deﬁnition of haplogroup A.
Statistics
The association of SNPs with CAG expansion was determined via
chi-square test on theallele frequencieswith abonferroni correction
when appropriate. Odds ratio is the fold increase of having the
disease if the speciﬁcallele ispresent ((Ad/Ancase)/(Ad/Ancontrol)),
where Ad¼ disease-associated allele; An¼ nondisease. Sensitivity is
a measure of how well a SNP allele correctly identiﬁes the disease
state (proportion of cases with the disease-associated allele (Ad/
AdþAn case)). Speciﬁcity is a measure of how well a SNP allele
correctly identiﬁes the control state (An/AdþAn control). Positive
predicted value (PPV) is the proportion of subjects with the
disease-associated allele who have the disease (Ad case/Ad case þ
Ad control). Negative predicted value (NPV) is the proportion of
subjects who do not have the disease-associated allele and do not
have the disease (An control/An case þ An control). When indi-
cated, a Student’s t test was performed for comparison between
two groups. One-way ANOVA was performed for more than two
groups with Tukey’s post-hoc comparison.
Results
SNP Validation and Characterization
A total of 190 SNPs were identiﬁed and veriﬁed in the HTT




Figure 1. Genetic Diversity Is Observed in the Human HTT Region
(A) Schematic representation of the location of 190 SNPs (red triangles) relative to the intron/exon structure of HTT. SNP 1 is located 50 of
the gene, whereas SNP 190 is the furthest 30 of the gene.
(B) Each of the 190 SNPs has a minor allele frequency (MAF) and the number of times each MAF occurs is plotted to demonstrate that there
is a large amount of diversity in the HTT region in the HapMap populations. 23% of SNPs were very common (MAF > 0.20). Many (45%)
rare SNPs (MAF < 0.05) were also detected.
(C) The MAF of each SNP is aligned for each ethnic population in the HapMap cohort. The pattern is similar for each ethnic group, although
the Yoruba have the most SNPs overall and tend to have higher MAFs.
(D) Plot of linkage disequilibrium (LD) in the HTT region in the HapMap cohorts. Linkage across HTT is relatively high (red is high LD, white
is low LD), enabling the use of tagging SNPs to sample the HD population. Chinese and Japanese have similar linkage and are pooled into
an Asian grouping. As expected, in both the MAF and the LD plot, the greatest diversity is seen in Yoruba relative to Europeans and Asians.in the promoter region, 11 exonic (coding), 157 intronic,
and 9 in the 30 UTR region ofHTT. For each SNP, the minor
allele frequency (MAF) was determined from the pooled
HapMap populations. A large proportion (23%) of the 190The AmeSNPs in the HTT region were common, having a MAF
of >0.20 (Figure 1B). These common SNPs will therefore
comprise themajority of diversity in the gene andheterozy-
gous individuals in these populations. The abundance ofrican Journal of Human Genetics 84, 351–366, March 13, 2009 353
common SNPs is important because it may present the
opportunity for allele-speciﬁc targeting of the disease-
carrying transcript. We also detected many rare SNPs (45%
of all SNPs) with a MAF < 0.05, a ﬁnding that is consistent
with previous studies (46% of SNPS with MAF < 0.05 in
ENCODE regions32).
To compare the genetic diversity of the HTT region
between ethnic groups, the MAF (Figure 1C) and pattern
of LD (Figure 1D) was plotted for each HapMap population.
Although there are clear similarities in the pattern of MAFs
between thepopulations, theYorubanpopulationexhibited
themost overall diversity, as expected.32,38,39 InYoruba, the
MAFs tend to be higher (and are therefore more frequently
heterozygous), and rare SNPs (MAF < 0.05) were observed
more often (Figure 1C). The amount of linkage disequilib-
rium (LD) across the gene region was less in the Yoruban
population relative to the other groups (Figure 1D). Phylo-
genetic analysis of individuals in the HapMap cohort is
consistent with a substantial amount of diversity in the
HTTregion,with thegreatest diversity inYoruba (Figure S2).
In contrast, the Asian group has fewer SNPs overall, lower
MAFs (Figure 1C), and highest LD (Figure 1D) relative to
the other groups.
SNP Frequency Distribution on HD Chromosomes
With the patterns of LD in the 190 validated SNPs, a panel
of 22 nonredundant tagging SNPS (tSNPs)40 was designed
to efﬁciently assess genotypes and construct haplotypes
in the HTT region. In order to determine which genotypes
came from each chromosome within each individual,
chromosomes were phased by CAG tract size. This allows
grouping of chromosomes by CAG tract size and compar-
ison of genotypes between the groups. HD patients (n ¼
65) of European ancestry were genotyped at the 22 tSNP
positions. Genotype information for disease chromosomes
(>35 CAG) and control chromosomes (<36 CAG) from
these HD patients is shown in Figure 2A. Allele counts
for the major (A) and minor (B) alleles are given at each
of the 22 tSNP positions.
HD chromosomes have a dramatically different allele
distribution compared to control chromosomes. Of the
22 tSNPs, more than half (12 SNPs) are signiﬁcantly associ-
ated with disease chromosomes (chi-square p < 0.0023;
alpha ¼ 0.0023 after bonferroni correction). For example,
at tSNP # 11, the allele distribution on the control chromo-
some (A-32, B-33) is signiﬁcantly different compared to the
disease chromosome (A-1, B-64) (chi-square p ¼ 1.7 3
1010). This signiﬁcant association is matched with an
extremely high odds ratio (OR ¼ 66) at this and other
SNP positions.
In addition to many tSNPs being signiﬁcantly associated
with disease chromosomes, some tSNPs have a single allele
that is a highly sensitive marker of disease chromosomes
(Figure 2). Sensitivity is a measure of how frequently
a speciﬁc allele occurs on a disease chromosome, and for
19 tSNPs the sensitivity is >0.85. It is important to note
thatnot all signiﬁcantly associatedSNPsarehighly sensitive354 The American Journal of Human Genetics 84, 351–366, Marchmarkers of disease chromosomes. For example, tSNP #11 is
a highly sensitivemarker of disease chromosomes (64/65¼
0.98)whereas tSNP#182 is not (34/65¼ 0.52). tSNP #182 is,
however, a speciﬁc marker (speciﬁcity 0.94) because of its
low MAF on general population chromosomes.
These data were conﬁrmed in a replication cohort of 203
HD patients. The same tSNPs were signiﬁcantly associated
with the disease chromosome (Figure S3). Surprisingly,
some tSNPs are not associated with disease chromosomes,
even in the combined cohort of 268 HD patients. For
example, at tSNP #63 the allele distributions between
disease (A-29, B-239) and control (A-14, B-254) chromo-
somes remain similar despite the fact that surrounding
tSNPs have extremely strong associations. The incomplete
allelic association and variable marker sensitivity is there-
fore not consistentwith a simple single-founder hypothesis
for the origin of HD chromosomes. This unusual pattern
across the gene region would require an unlikely series of
recombination events or signiﬁcantly different mutation
rates at different SNP positions.
SNP Frequency Distribution on 27–35 CAG
Chromosomes
Individuals with increased CAG tract size (27–35 CAG) rela-
tive to the general population are not at risk for developing
the signsandsymptomsofHD.However, childrenofparents
with 27–35 CAG may be at risk for inheriting a CAG allele
that has expanded in the disease range.8 New mutations
for HD have been shown to originate from this 27–35 CAG
population. Previous to this study, it has not been clear
whether the haplotype of 27–35 CAG chromosomes is
most similar to control chromosomes in the general popula-
tion or whether they have genetic similarities to chromo-
somes that have already expanded into the disease range.
In total, 66 chromosomes in the 27–35 CAG range were
phased and compared to 116 control chromosomes from
the general population (<27 CAG) at each of the 22 tSNP
positions (Figure 2B). The frequency of alleles on 27–35
CAG chromosomeswas signiﬁcantly different from control
chromosomes at 11 tSNP positions (chi-square p< 0.0023).
The odds of these speciﬁc tSNPs being associated with CAG
expansion is high (odds ratioR 3). Notably, these 11 out of
12 tSNP positions are also signiﬁcantly associated with HD
chromosomes.
ManytSNPsare also sensitivemarkersof27–35CAGchro-
mosomes. Eighteen tSNPs have a sensitivity ratio >0.85.
Notably, these 18 out of 19 tSNP positions were also sensi-
tive markers of disease chromosomes. Furthermore, similar
to HD chromosomes, not all tSNPs with signiﬁcant associa-
tions have a single allele that is a sensitive marker of 27–35
CAG. Again, tSNP #182 is signiﬁcantly associated with
27–35 CAG chromosomes (chi-square p ¼ 1.7 3 1007)
but not a sensitive marker (30/66 ¼ 0.45).
Control chromosomes all had similar allele frequency
distributions, regardless of the source of the control chromo-












(igure 2. Specific SNPs Are Highly Associated with CAG-Expanded Chromosomes
A) HD patient chromosomes were phased to allow comparison between the disease chromosome (>35 CAG) and control chromosome
ithin each patient (total 65 individuals). tSNP is identified by number and its position indicated relative to HTT. Alleles are either A
r B (major or minor). Allele counts are indicated (middle) and the frequency graphed (below). Twelve out of 22 tSNPs have a significantly
ifferent allele distribution between HD and control chromosomes (*chi-square p < 0.0023).
B) Allelic frequency on 27–35 CAG chromosomes is similar to disease chromosomes. Allele counts are indicated for phased control chro-
osomes (n¼ 116) and compared to 27–35 CAG chromosomes (n¼ 66) that contain an intermediate CAG tract size for HTT and may result
new mutations for HD in future generations. Eleven out of 22 tSNPs have a significantly different allele distribution between 27–35 CAG
nd control chromosomes (*chi-square p < 0.0023). These 11 associated tSNPs were found in both HD and 27–35 CAG chromosomes and
ppear to be common on CAG-expanded chromosomes.
C) There is no significant difference in the allele distribution between 27–35 CAG and HD chromosomes for any tSNPs.(<27CAG), whether they came from the general population
or the control chromosome(lowerCAG) fromHDpatientsor
control chromosomes of 27–35 CAG carriers (Figure S4).
The allele frequencies on 27–35 CAG chromosomes were
not signiﬁcantly different at any tSNP position (chi-square
p > 0.0023) from HD chromosomes (Figure 2C). TakenThe American Journal of Human Genetics 84, 351–366, March 13, 2009 355
Figure 3. CAG-Expanded Chromosomes Are Associated with Haplogroup A
(A) Three major haplogroups (A, B, C) are defined with 22 tSNP positions. The nucleotide defining each haplogroup at each tSNP is shown.
Variable tSNP positions are indicated (*). tSNPs with a gray box indicate nucleotide changes relative to haplogroup A. The amount of
similarity between the haplogroups is indicated by a neighbor-joining tree (right).
(B) Frequency distribution of haplogroups on HD (n ¼ 65), 27–35 CAG (n ¼ 66), and general population (n ¼ 116) chromosomes. CAG-
expanded chromosomes (>27 CAG) are enriched for haplogroup A relative to the general population. Chromosomes from the general pop-
ulation with <27 CAG phased for CAG size (right) demonstrate that high-normal CAG chromosomes also have an enrichment for hap-
logroup A relative to low-normal CAG chromosomes. The mean CAG tract size for each group is indicated.
(C) CAG size distribution for all chromosomes on haplogroups A or C. In the chromosomes used in this study, the mean CAG sizes for hap-
logroup A are significantly larger (p < 0.00001, t test) than haplogroup C. The high odds ratio on haplogroup A is an indication that CAG
expansion is much more likely to occur on haplogroup A chromosomes.together, these data suggest that as a group, 27–35 CAG
chromosomes and HD chromosomes are genotypically
similar across the HTT region.
Haplogroup Frequencies on CAG-Expanded
Chromosomes
Haplogroups were deﬁned manually with tSNPs that
are signiﬁcantly associated (p < 0.0023) and are highly
sensitive markers (>0.95) of disease chromosomes
(Figure 3A). Three major haplogroups (A, B, and C) could
be used to describe >96% of all chromosomes in our
study cohort of HD patients, 27–35 CAG individuals,
and controls from the general population. A neighbor-
joining phylogeny demonstrates that haplogroups A
and B are much more closely related than either are to
haplogroup C (Figure 3A). The ‘‘other’’ haplogroup
comprised singletons that could not be easily classiﬁed
into the deﬁned haplogroups and total only 4% of the
chromosomes.356 The American Journal of Human Genetics 84, 351–366, March 1HD chromosomes are almost exclusively (95%) hap-
logroup A (Figure 3B). In contrast, haplogroup A accounts
for only 53% of chromosomes from the general population
(<27 CAG). Haplogroup C was also very common on
control chromosomes (41%) but completely absent from
disease chromosomes. Similar to the HD chromosomes,
27–35 CAG chromosomes are enriched (83%) for hap-
logroup A relative to controls. It is also notable that each
individual from the general population (<27 CAG) could
be phased for high CAG and low CAG within the normal
range, the higher CAG (mean CAG ¼ 19.85 2.7) chromo-
some was also statistically enriched (chi-square p ¼ 0.041)
for haplogroup A (62%) relative to the low CAG (mean
CAG ¼ 17.35 2.1) chromosome (43%).
TheCAGsizes for all chromosomes from10–50CAG-con-
taining haplogroup A or C are plotted in Figure 3C. For the
chromosomes used in this study, the mean CAG size for
haplogroup A (33.9 5 11.7) is signiﬁcantly (p < 0.00001,
t test) greater than that for haplogroup C (18.9 5 5.9).3, 2009
Although haplogroup A and C are both found on control
chromosomes (<27 CAG), haplogroup A is uniquely
enriched on chromosomes with an expanded CAG tract.
Even when considering only control chromosomes
(<27 CAG), the mean CAG of haplogroup A (18.8 5 3.0)
has a small but signiﬁcant increase (t test p < 0.00001)
compared to haplogroup C (mean ¼ 17.5 5 2.3). The
odds ratio of haplogroup A (odds ratio 8.4, 95% CI from
4.6–15.6, chi-square p ¼ 5.9 3 1014) indicates that chro-
mosomes>26CAGare 8.4-foldmore likely tooccur onhap-
logroup A than other haplogroups. In comparison, the low
odds ratio of haplogroup C (odds ratio 0.1, 95% CI from
0.03–0.17, chi-square p ¼ 1.2 3 1013) indicates that this
haplogroup is signiﬁcantly protected fromCAGexpansion.
Variants of Haplogroup A on CAG-Expanded
Chromosomes
Haplogroup A is present on almost all CAG-expanded chro-
mosomes but only ~50%of control chromosomes. Todeter-
minewhether thereweredifferences betweenhaplogroupA
when found on disease and control chromosomes, hap-
logroup A was subdivided into variants by subtracting the
core elements that deﬁne haplogroup A and assessing the
tSNPs that remain. Haplogroup A was deﬁned by 10 tSNPs
(3, 11, 14, 22, 65, 89, 97, 119, 169, and 178), so the hap-
logroup variants are deﬁned by tSNPs at the remaining
positions (tSNP 1, 55, 63, 69, 80, 95, 112, 176, 181, 182,
185, and 190). Haplogroup variants A1–A5 capture 98% of
all haplogroup A chromosomes (Figure 4A). The remaining
2% of haplogroup A chromosomes were classiﬁed as
‘‘other,’’ because they were singletons difﬁcult to classify
into variant groupings.
Of all of the HD chromosomes on haplogroup A, the
majority (55%) can be classiﬁed as variant A1 (Figure 4A).
Chromosomes with 27–35 CAG are also enriched for
variant A1 (53%). In contrast, variants A4 andA5 are almost
absent from expanded CAG chromosomes. Control chro-
mosomes from the general population (<27 CAG) have
a more even mixture of variants A1–A5. It is notable that
in the general population (<27 CAG), variant A1 occurs
more than three times more frequently on chromosomes
withhigh-normalCAGversus low-normalCAG (Figure 4B).
The distribution of CAG sizes for all chromosomes
carrying each haplogroup A variant is plotted in
Figure 4C. Variant A1 occurs on chromosomes that range
from 12 to 50 CAG, with the distribution shifted toward
CAG expansion (mean CAG ¼ 38.8 5 9.5). Variant A2
also occurs on a range of CAG sizes extending from
low normal (CAG 15) to high expanded (CAG 49) with
an upward shift in mean CAG size (35 5 11). Variant
A3 has a bimodal distribution around normal and CAG-
expanded chromosomes (mean CAG ¼ 285 12). Variants
A4 (mean CAG¼ 205 8) and A5 (mean CAG¼ 175 5) are
predominantly found on chromosomes with <27 CAG.
The mean CAG is signiﬁcantly different in all variants,
with the exception of A4 versus A5 (p < 0.001, one-way
ANOVA, Tukey posthoc).The AmeVariant A1 confers the greatest odds ratio of CAG expan-
sion (i.e., chromosomes with variant A1 are 6.5 times
more likely to carry a CAG expansion, 95% CI from 3.5–
12.3, chi-square p¼ 8.53 1010). Variant A2 chromosomes
are almost equally likely to carry a normal or expandedCAG
(odds ratio 1.1, 95%CI from0.6 to 1.9, chi-square p¼ 8.33
101). Variant A3 is almost twice as likely to contain
a normal CAG versus expanded (odds ratio 0.5, 95% CI
from 0.3 to 0.99, chi-square p ¼ 4.3 3 102), whereas vari-
ants A4 and A5 are unlikely to carry a CAG expansion
(odds ratio is close to 0, chi-square 95% CI from 0.00 to
0.25, p ¼ 1.23 106 and 1.83 103, respectively).
Loss of CAG tract interruption has been reported to
confer increased CAG instability inHTT.41–44 To determine
whether the increased odds ratio of CAG expansion in A1
and A2 was due to loss of CAG tract interruption on these
variants, direct sequencing was performed in exon 1 of
HTT. Loss of interruption was not found in 10 HD and
intermediate allele individuals sequenced, indicating no
association between the risk haplotypes and loss of CAG
tract interruption.
Taken together, these data suggest that there is an enrich-
ment of speciﬁc haplotype variants on CAG-expanded
chromosomes. Variants A1 and A2 confer the highest
risk for having a CAG-expanded chromosome, whereas
A4 and A5 variants are extensively protected from CAG
expansion.
Haplogroups in the HapMap Cohort
We next wanted to determine whether the frequency of
haplogroup A could account for differences in the preva-
lence of HD in ethnic groups in the HapMap populations.
With the same haplogroup deﬁnitions (Figures 3 and 4),
the frequency of haplogroups in each ethnic group is
shown in Figure 5.
Interestingly, the frequency of haplogroup A is similar
in Europe (46%), China (44%), and Japan (49%), even
though the prevalence of HD in Asian populations (0.11
to 0.72 affected persons per 100,00029,45–48) is reported
to be much lower than in Europe (5 to 7 per 100,0002).
However, further analysis reveals that the Chinese and
Japanese general population cohorts lack the presence of
variants A1 and A2, the two variants with the highest
odds ratio for CAG-expanded chromosomes. They also
have a very high frequency of A5, a variant that is pro-
tected from CAG expansion.
African black populations were historically believed to
have a low prevalence of HD.49 Accordingly, the general
population in Yoruba lacks the risk haplotypes and is
greatly enriched for the protective A4 variant. Although
recent studies suggest that the prevalence in South African
blacks may be higher than originally reported,50,51 the
prevalence of HD has not been directly measured in the
Yoruban people of Nigeria. The Yoruban population also
has a very high proportion of ‘‘other’’ haplogroups,
composed of nonmatching haplotypes, which reﬂects
the greater genetic diversity in this population.rican Journal of Human Genetics 84, 351–366, March 13, 2009 357
Figure 4. Specific Haplogroup A Variants Are Enriched on CAG-Expanded Chromosomes
(A) To determine whether there are differences in haplogroup A chromosomes from CAG-expanded and normal chromosomes, haplogroup
A was divided into five major variants by subtracting the common tSNPs (light gray text) and with differences at the 12 remaining tSNP
positions (black text). The wildcard asterisk (*) is used for variable allele positions. Dark gray boxes indicate differences relative to the A1
variant. The relationship between the variants is shown by a neighbor-joining tree (right).
(B) CAG-expanded chromosomes (HD, N¼ 62; 27–35 CAG carriers, n¼ 55) have similar haplogroup A variant distributions and are specif-
ically enriched for A1 and A2 relative to chromosomes from the general population (n ¼ 61). Phased chromosomes from the general pop-
ulation (right) demonstrates that large-normal chromosomes also have an enrichment for variant A1 and A2 relative to low-normal chro-
mosomes. Variants A4 and A5 are almost absent from CAG-expanded chromosomes.
(C) CAG size distribution of chromosomes in each of subgroup. Variants A1, A2, and A3 chromosomes have a broad CAG size distribution
that extends from low normal (<16 CAG) to high (>50). For the chromosomes used in this study, the mean CAG size and odds ratio of each
variant is indicated. The highest HD risk variants, A1 and A2, have significantly elevated mean CAG size and odds ratios >1. Variant A3 is
a moderate HD risk haplotype, because it has a larger component of CAG sizes in the normal range and therefore a lower mean CAG size.
Chromosomes with variant A4 or A5 are stable in the normal range.358 The American Journal of Human Genetics 84, 351–366, March 13, 2009
Figure 5. Ethnic Groups that Have a Low
Prevalence of HD Do Not Have HD Risk
Haplotypes in Their General Population
The prevalence of HD is much higher in
Western European populations relative to
Asia and Africa. Although the frequency of
haplogroup A is similar between Europe
and Asia (A), the frequencies of the high-
risk variants of haplotype A, A1 and A2,
are not found in the Asian populations
(B). As expected, there is more genetic
diversity in the Yoruba population, with
a lower level of risk haplotypes and a rela-
tively greater frequency of ‘‘other’’ haplo-
types. Number of chromosomes assessed in
each ethnic group is indicated in brackets.The frequency of the haplogroup A variants appears to
be signiﬁcantly associated with differences in HD preva-
lence. Risk haplogroup variants for CAG expansion (A1
and A2) are absent and protected haplogroup variants
(A4 and A5) are muchmore frequent in ethnic populations
with a low prevalence of HD.
Identifying Targets for Allele-Speciﬁc Silencing
of Mutant htt
Gene silencing has great potential for the treatment of HD
and other trinucleotide repeat disorders.52 To facilitate
allele-speciﬁc gene silencing technologies for HD patients,
we sought todeterminewhether thepatternof disease-asso-
ciated alleleswould allow the efﬁcient and speciﬁc targeting
of the mutant chromosome in the HD patient population.
Because of the considerable expense involved in the clinical
development of each target, it is important to be able to
maximize the potential coverage of the HD population
with a minimum number of allele targets (by using anti-
sense oligonucleotides for gene silencing). A patient would
theoretically be eligible for allele-speciﬁc treatment with
a single targetingoligonucleotide if genotypingdetermined
that they were heterozygous at the target SNP with the
correct target allele associated with the disease chromo-
some. A crucial question is: Which target (or set of targets)
would most efﬁciently cover the HD patient population
and thereforebeappropriate choices fordrugdevelopment?
We report the coverage of the HD patient cohort in this
study by using target panels comprising between 1 and
4 SNP targets (Figure 6). Multiple SNP combinations consti-
tute each panel (Figure S5). Patient ‘‘coverage’’ is deﬁned as
the percent of the population of known genotypes that
would be eligible for treatment. Sevenof the 65HDpatients
were not heterozygous at any SNP position, and therefore
the maximum theoretical coverage is 89% (58/65). The
maximum coverage by any single SNP was 52% (tSNP
182). Panels including 4 or 5 SNPs provided only a small
increase in the coverage compared to the 3 SNP panel,
which targeted all but 3% of the theoretically targetable
HD patients in the cohort. In addition to the tSNP targetsThe Amereported here, further SNPs in LD with these SNPs will also
serve as equally suitable targets, providing further ﬂexibility
to oligonucleotide design. Many technical challenges
remain pertaining to oligonucleotide design for efﬁcient
and speciﬁc silencing, but the presence of SNPs strongly
associated with disease chromosomes provide an attractive
opportunity for thedevelopmentof allele-speciﬁc targeting.
Discussion
In this comprehensive analysis of the HTT region, we vali-
dated 190 HapMap SNPs and genotyped 22 nonredundant
Figure 6. Disease-Associated SNPs Can Be Efficiently Targeted
for Allele-Specific Silencing of the Mutant HTT mRNA
In an HD patient whose genotype is known, specific heterozygous
alleles can be used to distinguish the CAG-expanded mRNA from
nonexpanded mRNA (i.e., alleles that are 100% sensitive of the
disease allele and 100% specific). Because of the expense of clin-
ically testing and validating each target, it is important to maxi-
mize the patient coverage with a minimum number of targets. A
theoretical maximum number of targetable patients (89%) exists
because in this cohort, 7 of the 65 HD patients were not heterozy-
gous at any tSNP and therefore could not be targeted. The
maximum percent of the HD population in this study that could
be treating with a single target (disease-associated allele) is
52%. The development of a therapy toward a second allele target
would increase the patient coverage to 80%.rican Journal of Human Genetics 84, 351–366, March 13, 2009 359
tagging SNPs from HD (>36 CAG), intermediate allele
(27–35 CAG), and control (<27 CAG) chromosomes
from individuals of European origin. We ﬁnd the distribu-
tion of genotypes to be signiﬁcantly different between
CAG-expanded chromosomes (>26 CAG) and control
chromosomes in the normal CAG range (<27 CAG).
The disease-associated SNPs constitute a cluster of
similar haplotypes (haplogroup A) found on 95% of
disease chromosomes (odds ratio ¼ 8.4, chi-square p ¼
5.9 3 1014).
The association ofmany SNPs with CAG-expanded chro-
mosomes is much stronger than previously reported poly-
morphisms in HTT15–30 and are conﬁrmed in a replication
cohort. In addition, we now show that many SNPs are
sensitive markers of disease chromosomes, meaning that
a single SNP allele was almost always associated with
CAG-expanded chromosomes. Importantly, two variants
of haplogroup A (A1 and A2) were dramatically and specif-
ically enriched on HD chromosomes and are therefore at
increased risk for CAG expansion (odds ratio 6.5 and 1.1,
respectively).
Interestingly, the same set of sensitive allelic markers
and associated SNPs are also observed on chromosomes
from 27–35 CAG carriers who are unaffected by HD but
may be at risk of transmitting a chromosome that has
expanded into the affected CAG range. Similar to disease
chromosomes, haplogroup A was found on the majority
(83%) of 27–35 CAG chromosomes.
There were no signiﬁcant differences in SNP association
between HD and 27–35 CAG chromosomes, suggesting
that de novo mutations for HD continue to occur on the
same haplogroup background as the rest of the HD popu-
lation. These data suggest that chromosomes with CAG
expansions above the normal range (>26 CAG) arise on
a few haplotype variants that contain common elements
that confer predisposition to expansion.
Origins of HD Mutations
The prevalence of HD is inﬂuenced by the balance between
CAG-expanded chromosomes that are eliminated from the
population because they are not transmitted to the next
generation (i.e., juvenile HD) and new mutations occur-
ring in families without a history of HD. The level of insta-
bility is greater for longer uninterrupted CAG repeat tracts
and these are biased toward expansion.53 What factor(s)
determine which chromosomes will be unstable and
undergo progressive CAG expansion over many genera-
tions? We propose three basic population models of CAG
expansion in HTT.
Model I: Stochastic Expansion
If CAG expansion occurs randomly, then chromosomes
with an equal CAG tract size should have an equal proba-
bility of expansion. Therefore, this stochastic model,
where local DNA sequence has little inﬂuence on the
CAG instability, would predict that the diversity of haplo-
types in HTTwould be similar in both HD patients and the
general population (Figure 7, I).360 The American Journal of Human Genetics 84, 351–366, MarchThis strictly stochastic model is clearly not supported by
the current data. The vast majority of CAG-expanded chro-
mosomes in the European population are found only on
speciﬁc haplogroup variants (A1 and A2). Both longer-
normal (20–26 CAG) and intermediate allele (27–35
CAG) chromosomes are speciﬁcally enriched for the
same haplogroup as the HD patients. Notably, there are
haplogroups (C) and haplogroup variants (A4 and A5) on
which CAG expansion almost never occurs. CAG expan-
sion occurs preferentially on speciﬁc haplotypes and is
therefore not a stochastic process.
Similarly, if genetic trans-factors or environmental inﬂu-
ences are the primary determinants of CAG instability in
HTT (Figure 7, I), we would not expect a dramatic enrich-
ment of a speciﬁc HTT haplogroup with CAG expansion.
If factors such as mutations in mismatch repair genes,
the age of parents, or environmental toxins alone were
sufﬁcient to cause CAG instability, we would not expect
the majority of CAG-expanded chromosomes to be
restricted to a limited number of haplotypes.
Model II: Founder Chromosome
The presence of HD chromosomes on a single haplogroup
could be due to the coincidental linkage ofmarkers with an
initial (founder) CAG-expansion event. In this model,
a single (or limited number) of chromosomes underwent
a large expansion in CAG size, and all CAG-expanded
chromosomes are derived from this founder (Figure 7, II).
A variation of the founder hypothesis would be a rare
mutational event that resulted in an intermediate or
large-normal allele, producing a pool of chromosomes
not affected by HD, but at risk for expansion in later gener-
ations because of their larger-than-normal CAG size, such
as observed in Friedreich Ataxia (FRDA [MIM 229300])54
and speciﬁc populations of Myotonic Dystrophy 1 (DM1
[MIM 160900]).55–58
The pattern of SNPs on HD chromosomes is not consis-
tent with a founder CAG-expansion event for several
reasons: (1) there are multiple haplogroup variants (A1
and A2) associated with CAG expansion that are not easily
derived from one another; (2) the pattern of strong SNP
linkage to CAG expansion is punctuated, rather than de-
caying as a function of genetic distance; and (3) there are
no haplotypes found only on CAG-expanded chromo-
somes and not on control chromosomes, as would be ex-
pected from a stratiﬁed founder population.
(1) Unlike other trinucleotide repeat diseases believed to
originate from a founder chromosome, CAG-expanded
chromosomes in HD arise on multiple haplogroup vari-
ants. DM1, for example, is believed to arise from a founder
chromosome with a large-normal CTG tract in the DMPK
gene (MIM 605377), which serves as a reservoir for
expanded CTG chromosomes because of its already large-
normal CTG size.55 This single haplotype is associated
with CTG-expanded chromosomes at numerous consecu-
tive markers.57 French Canadian DM1 families, for
example, were found to contain a core 500 kb region of
identical sequence consistent with a single ancestral13, 2009
Figure 7. Pattern of Disease-Associ-
ated SNPs Is Consistent with a Model of
Stepwise CAG Expansion on a Predispos-
ing Haplogroup
Schematic of possible models of CAG
expansion. Arrows represent mutational
events that result in a change in CAG tract
size across generations on specific chromo-
somal haplogroups.
(I) Stochastic model results in essentially
unpredictable CAG expansion over many
generations. If the primary factors influ-
encing CAG instability are other than cis-
elements (i.e., genetic trans-factors, envi-
ronmental influences, or entirely stochastic
processes), then CAG expansions should
occur randomly on chromosomes with
randomgenotypes. HD chromosomes should
therefore have a distribution of haplo-
groups similar to the general population.
(II) The expanded CAG founder (or large normal founder) model predicts a rare and large expansion in the CAG tract in a limited number of
individuals. CAG instability then results because of the overall increase in CAG tract size. All HD individuals are related to the founder
chromosome(s) and would be expected to have an identical haplogroup except for instances where recombination events have occurred.
The founder population is genetically isolated from the general population and unique haplotypes should arise on CAG-expanded chro-
mosomes only.
(III) The predisposing haplogroup model predicts that CAG expansion occurs primarily on a haplogroup containing predisposing cis-
elements. The cis-elements may interact with trans-factors or environmental influences, but the predisposing haplogroup (containing
the cis-elements and polymorphisms in LD with the cis-elements) is required for instability to occur and is therefore the predominant
haplogroup of disease chromosomes. The source of the predisposing haplogroup is not unique to intermediate-sized CAG alleles, so
the origin of unstable CAG chromosomes is the general population carrying the predisposing cis-elements. The significant enrichment
of HD on haplogroup A is most consistent with model III.founder.56 This is in contrast to European HD chromo-
somes, where the strength of allele associations is variable
across the gene region. CAG expansion in HD arose
multiple times on haplogroup variants that are not easily
derived from one another but share elements in common.
(2) Although there are numerous SNPs (12/22) spanning
the gene region that are both highly associated with and
sensitive markers of CAG-expanded chromosomes, these
are punctuated with other SNPs (6/22) that completely
lack association with CAG expansion. If HD chromosomes
were derived from a founder, they would be expected to
have identical alleles at all SNP positions close to the muta-
tion, with the strength of linkage decaying as a function of
nucleotidedistance and recent recombinationevents.59 It is
difﬁcult to reconcile the lack of association and allele spec-
iﬁcity interspersed across the gene (i.e., tSNP 63, 80, 112,
and 182) with a recent single-founder hypothesis for HD.
(3) These data are not consistent with a founder or large-
normal CAG founder for HD because the speciﬁc disease-
associated haplogroup variants are also prevalent in the
general population (25%). A large-normal CAG founder
would be expected to result in a genetically isolated popula-
tion inwhichuniquehaplotypeswill arise. This is the case in
FRDA, where the disease-associated haplotype from a long-
normal founder is infrequent in the general population
(4%).54 In theEuropeanpopulation, there arenohaplotypes
that were unique to CAG-expanded HD chromosomes.The AmeModel III: Predisposing Haplogroup
The current data are most consistent with CAG expansion
occurring on haplotypes that are predisposed for CAG
instability (Figure 7, III). These haplotypes may contain
DNA cis-elements that either introduce instability them-
selves or whose afﬁnity for repeat-stabilizing factors has
been compromised. The stability of other trinucleotide
repeats in the genome is inﬂuenced by cis-elements,60–62
including speciﬁc identiﬁed features such as the replica-
tion origin63 and sequences that contribute to the forma-
tion of secondary structures.64 Recently, it has been shown
that mutation or methylation of the CTCF binding site
adjacent to the CAG-tract of ATXN7 (MIM 607640)
promotes repeat instability in a mouse model of Spinocer-
ebellar Ataxia 7 (SCA7 [MIM 164500]).65
A loss of CAG tract interruption (resulting in an extended
pure CAG tract) is an example of another cis-element that
plays an important role in instability in other CAG repeat
diseases, such as Myotonic Dystrophy 2 (DM2 [MIM
602668]),66 FRDA,54 Fragile X (MIM 300624),67 SCA1
(MIM 164400),68 and SCA17 (MIM 607136).69 However,
this loss of interruption occurs only rarely in HTT41–44
and is not associated with the haplogroup variants with
the highest risk of CAG expansion.
It is not clear what cis-elements on haplogroup variants
A1 and A2 are increasing CAG instability in HTT. The
complementary hypothesis is that cis-elements on therican Journal of Human Genetics 84, 351–366, March 13, 2009 361
non-HD haplogroups (primarily haplogroup C and hap-
logroup A variants A4 and A5) provide stability to the
CAG tract. Of particular interest are the tSNPs that distin-
guish haplogroup A from haplogroup C (tSNP 11, 14,
and 89) and other unknown polymorphisms in LD with
these. Because of the punctuated pattern of allele associa-
tions, multiple cis-elements may singly or cumulatively
inﬂuence CAG stability.
Importantly, the haplogroup variants with the highest
risk of CAG expansion (A1 and A2) are also found on
general population chromosomes. This suggests that
multistep expansions into the HD-affected range occur
from a reservoir of normal alleles containing the predis-
posing cis-elements. These high-risk variants exist in
a subset of the general population of Europe and allow
prediction of which families may experience CAG expan-
sion in future generations. It is plausible that the majority
of European HD cases are due to initial cis-element muta-
tions in HTT in the general population that increased
CAG instability (rather than the founder mutation being
the CAG expansion itself).
Although we can predict which chromosomes may be
susceptible to CAG expansion, when CAG tracts expand
appears to be more stochastic and could have many inﬂu-
ences. In the presence of the predisposing haplotype,
trans-factors (i.e., DNA repair genes11), environmental
inﬂuences (sex and age of the transmitting parent, diet,
toxins), and primarily the length of uninterrupted CAG
repeats will inﬂuence the timing and level of CAG expan-
sion on transmitted chromosomes.
Geographic Variability in HD
We ﬁnd that haplogroup A variants with the highest odds
ratio for CAG expansion (A1 and A2) are not present in
ethnic populations with a low prevalence of HD (Figure 5).
Epidemiological reports have established prevalence rates
ranging from 5 to 10 affected persons per 100,000 in coun-
tries of Western European ancestry, including the United
States and Canada.70–73 Considerably reduced frequencies
of HD have been reported in Japan,29,45,46 China,47,48
Finland,74 South African black populations,49–51 and
North American black populations.71 The presence of the
predisposing haplogroup variants in the general popula-
tion of Western Europe provides a compelling explanation
for the >10-fold increase in prevalence relative to other
ethnic groups.
In the few cases where expansions have occurred on
low-risk haplogroup variants—both in the European and
other ethnic groups—it is possible that a low background
level of stochastic expansion (model I) may allow for
CAG expansion in the absence of predisposing cis-
elements. The molecular mechanism of CAG instability
may be different between stochastic expansion and CAG
expansion on a predisposing haplotype. Future studies
will need to control for haplotypes when assessing the
detailed mechanisms of CAG instability at the molecular
level.362 The American Journal of Human Genetics 84, 351–366, March 1Gene Silencing
Several lines of evidence suggest that gene silencing of the
mutant HTT could be a successful treatment for HD.
Previous studies in mouse models of HD have demon-
strated that the severity of the disease is dependent on
the level of expression of the mutant gene.75–82
However, wild-type huntingtin has a crucial function
during development of the nervous systemand a protective
role in cells.83,84 Constitutive knockout of HTT is lethal
during embryonic development85–87 andadult inactivation
of HTT leads to progressive degeneration in the brain and
the testes.88 In addition, because of aggregation, the half
life of mutant htt may be longer than WT htt, and non-
allele-speciﬁc silencing might increase the ratio of mutant
to wild-type htt and worsen the disease phenotype. Allele-
speciﬁc silencing of the mutant gene would be desirable
to avoid the potentially negative consequences of reducing
huntingtin expression from the wild-type allele.
Precise silencing of genes or nucleic-acid gene products
can be achieved with sequence-based targeting methods,
such as RNA interference (RNAi) technology, antisense
oligonucleotides (ASO), microRNA (miRNA), or small
hairpin interference RNA (shRNA). Unfortunately, the
CAG tract expansion that causes HD cannot be targeted
directly because of its size and repetitive nature. Instead,
SNPs that are in LD with expanded CAG alleles would be
attractive surrogate targets for allele-speciﬁc gene silencing
of mutant HTT.
The high degree of linkage observed between disease
chromosomes and speciﬁc alleles provides the therapeutic
opportunity to selectively knock down the disease allele.
Allele-speciﬁc silencing of mutant HTT has been recently
achieved in patient-derived ﬁbroblasts with RNAi.89,90
It now becomes important to identify which disease-
associated SNP alleles most efﬁciently target the HD
patient population. The expense of drug development for
each target is considerable, and it is therefore important
to maximize patient population coverage with a minimum
number of therapeutic targets. With this information on
efﬁcient targets, the challenge becomes the development
and testing of oligonucleotides that effectively and specif-
ically silence the mutant allele. The information provided
here (Figure 6; Figure S5) will enable multiple technologies
for this purpose.
Conclusions
CAG expansion in HTT is strongly associated with a set of
SNPs that constitute a single haplogroup. The data are
consistent with a multistep model for CAG expansion in
HD and provides evidence that CAG instability is most
likely to occur on predisposing haplotypes containing
speciﬁc cis-elements. The high prevalence of HD in Euro-
peans relative to other populations may be due to an initial
cis-element mutation in the European general population,
which conferred a greater probability of CAG instability.
Because of this, we hypothesize that there exists a subpop-
ulation of unaffected carriers (both intermediate allele and3, 2009
in the general population) that have a predisposition to
CAG expansion and may result in new mutations for HD
in future generations.
These data are not consistent with the HD mutation
occurring randomly or primarily as a result of genetic
trans-factors or environmental inﬂuences because CAG
expansion occurs on speciﬁc, nonrandom haplogroup
variants. The pattern of allele associations and the popula-
tion distribution of these at-risk haplogroup variants make
them unlikely to be the result of a founder CAG expansion
for the origins of HD.
Many of the SNPs highly associated with CAG expan-
sion do not segregate independently and are in LD with
each other. Future studies will seek to identify which
SNPs may point to cis-elements for CAG instability in
HTT. Finally, the strong LD between a speciﬁc haplogroup
and CAG-expanded chromosomes provides an opportu-
nity for the therapeutic development of personalized
medicine in HD. The efﬁcient allele-speciﬁc targeting of
mutant huntingtin in the majority of HD patients may
require the clinical validation of only a small number of
targeting oligonucleotides.
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